Takeda And Cell Genesys Ink $270 Million Development Deal for GVAX Immunotherapy

PERTH, Australia - Japan-based Takeda and San Francisco-based Cell Genesys formed a global development alliance for Cell Genesys's lead product GVAX immunotherapy for prostate cancer, currently in Phase III trials

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip